Effect of Remimazolam on Induction and Maintenance of General Anesthesia in Kidney Transplant Patients
Lini Chen,Weiyong Qin,Jiangdong Wu,Guilin Zhao,Xiaoqing Jiang,Minghui Li,Zijin Huang,Xueke Du
DOI: https://doi.org/10.2147/ijgm.s464530
IF: 2.145
2024-05-28
International Journal of General Medicine
Abstract:Lini Chen, &ast Weiyong Qin, &ast Jiangdong Wu, Guilin Zhao, Xiaoqing Jiang, Minghui Li, Zijin Huang, &ast Xueke Du &ast Department of Anesthesiology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People's Republic of China &astThese authors contributed equally to this work Correspondence: Zijin Huang; Xueke Du, Department of Anesthesiology, the Second Affiliated Hospital of Guangxi Medical University, No. 166 of Daxue East Road, Nanning, Guangxi, 530007, People's Republic of China, Tel +86-13768114848 ; Tel +86-17307711159, Email ; Purpose: This study aims to evaluate the effect of remimazolam on induction and maintenance of general anesthesia in kidney transplant patients. Methods: 120 patients undergoing kidney transplant were divided into two groups: Propofol group (Group P) and Remimazolam group (Group R). Anesthesia induction: remimazolam had injected IV at a dose of 0.15– 0.35 mg/kg in Group R, while propofol had injected IV at a dose of 2.0– 2.5 mg/kg in Group P. Anesthesia maintenance: remimazolam was injected IV at a dose of 0.3– 1.0 mg·kg − 1 ·h − 1 and propofol was injected IV at a dose of 1– 12 mg·kg − 1 ·h − 1 in Group R, propofol was injected IV at a dose of 3– 12 mg·kg − 1 ·h − 1 in Group P. All patients have the same remaining anesthesia durgs. Results: Compared with Group P, in Group R the time of disappearance of the eyelash reflex and the time to drop to 60 in BIS was longer ( P < 0.05), the time of awakening was shorted ( P < 0.05), the MAP of T 6 was fluctuated less ( P < 0.05), the incidence of hypotension and injection pain during induction was reduced ( P < 0.001), the incidence of intraoperative bradycardia during operation was reduced ( P < 0.05), the dosages of sedatives drug during maintenance was reduced ( P < 0.05). There was no statistically significant difference in postoperative renal function between the two groups of patients ( P > 0.05). Conclusion: Remimazolam can be safely and effectively used for the induction and maintenance of general anesthesia in kidney transplant patients. Keywords: remimazolam, propofol, general anesthesia, kidney transplant Propofol, a widely used sedative in clinical anesthesia, has the characteristics of fast sedation, short action time, rapid and complete awakening, etc, however, it has strong inhibitory effect on circulatory function, which can cause a significant decrease in blood pressure by directly inhibiting myocardial contraction and dilating blood vessels. 1 Moreover, it is prone to inducing injection pain during the infusion process. 2 Furthermore, prolonged and high-dose intravenous infusion of propofol can cause propofol infusion syndrome. 3 Remimazolam, as a new benzodiazepine sedative drug, has the characteristics of fast onset, short duration of action, no liver or renal metabolism, minor impact on the cardiovascular system, no injection pain, and can be antagonized by the benzodiazepine receptor antagonist flumazenil. 4 Currently, remimazolam is mainly used for sedation during gastroscopy and colonoscopy, as well as induction and maintenance of general anesthesia. 5,6 But the effect of remimazolam on induction and maintenance of general anesthesia in patients undergoing kidney transplant has yet to be explored. This study aims to evaluate the effect of remimazolam on induction and maintenance of general anesthesia in patients undergoing kidney transplant, providing a basis for clinical application. This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Second Affiliated Hospital of Guangxi medical University (2022-KY-0150). It was registered at the Chinese Clinical Trials Registry (ChiCTR2200061051). All donor organizations in this study were sourced from deceased citizens and voluntarily donated with the informed consent of their families, and that this was conducted in accordance with the Declaration of Istanbul. Before the operation, all patients to participate and their families also signed and informed consent form. This was a randomized, single-blind, prospective controlled clinical trial. 120 patients undergoing kidney transplant from June 2022 to June 2023 who underwent elective tracheal intubation and general anesthesia, gender unlimited, aged 18–65 years, with a body mass index (BMI) of 18–30 kg/m 2 and an American Society of Anesthesiology (ASA) physical status of III-IV. Patients were excluded according to the following criteria: Non first-time kidney transplant patie -Abstract Truncated-
medicine, general & internal